Entry Detail
| General information | |
| Database: | DB00683 |
| Objective: | The purpose of this study was to evaluate the safety and efficacy of the combination of sorafenib and bevacizumab in patients with advanced neuroendocrine tumours. |
| Authors: | Castellano D, et al |
| Title: | A doseescalatingphase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. |
| Journal: | Eur J Cancer. |
| Year: | 2013 |
| PMID: | 24012098 |
| Trial Design | |
| Clinical Trial Id: | NA |
| Agent: | Sorafenib and bevacizumab |
| Target: | NA |
| Cancer Type: | neuroendocrine tumour |
| Cancer Subtype: | advanced neuroendocrine tumours |
| Therapy Type: | com |
| Therapeutic Combination Type: | 1 |
| Therapeutic Combination Content: | sorafenib+bevacizumab |
| Study Type: | Openlabel, uncontrolled, multicenter, phase II clinical trial |
| Key Patients Feature: | Eligible patients had histologically confirmed measurable advanced NETs (carcinoid tumour, includingbronchial location; islet cell carcinoma; or other moderately or welldifferentiated tumours). Eligibility criteriaincluded age P18 years; Eastern Cooperative OncologyGroup (ECOG) performance status of 0-2; adequate haematological, liver and renal function (defined asabsolute neutrophil count P 1.5 109 /L; total platelets P 100 109 /L; total bilirubin 62 upper limit ofnormal (ULN), AST and ALN 63 ULN (or <5 ULN in hepatic metastasis); total creatinine level61.5 ULN) and a life expectancy of at least 24 weeks.Measurable disease was required for all patients. |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | sorafenib 200mg bid (days 15 of each week) and bevacizumab 5mg/kg once every 2 weeks (day 1, week 1). Tumour response was performed according to RECIST (v1.0) every 2 months during the treatment period. Adverse events were graded according to CTCAE (v3.0). |
| Primary End Point: | progression free survival rate (PFSR) after 6 months of treatment with the combination of sorafenib and bevacizumab. |
| Secondary End Point: | overall progression free survival(PFS), time to progression (TTP), overall survival (OS) and safety and tolerability,disease control rate and objective response rate |
| Patients Number: | 44 |
| Trial Results | |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | NA |
| Median Time to Progression: | 14.5 months (95%CI: 9.7not achieved) in patients with the combination therapy. |
| Median PFS A vs. C: | in patients with the combination therapy was 12.4 months (95% confidence interval (CI): 9.4-16.2). Median PFS by type of tumour was 11.4 (95%CI: 8.9-16.2) months forcarcinoid tumours and was not reached for pancreatic tumours. |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | The most common AEs were asthenia, hand-foot syndrome (HFS), mucositis, diarrhoea and hypertension. Less than 10% of patients had haematologic toxicities (two patients leukopaenia and one patient anaemia). |
| Conclusions: | Sorafenib and bevacizumab combination showed clinical benefit but unfavourable safety results compared with drugs in monotherapy. Further development of this combination is not warranted and a sequential approach is recommended instead. |